News stories about Syros Pharmaceuticals (NASDAQ:SYRS) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.6296085134536 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Syros Presents PK & PD Data at ESMO for SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML & MDS… (ih.advfn.com)
- Oversold Conditions For Syros Pharmaceuticals (SYRS) (thestreet.com)
- Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients (finance.yahoo.com)
Several research analysts recently issued reports on SYRS shares. Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Syros Pharmaceuticals in a research note on Tuesday, May 16th. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Oppenheimer Holdings, Inc. set a $28.00 target price on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, June 12th. Finally, Cann reissued a “buy” rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a research note on Monday, August 21st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Syros Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $22.97.
Syros Pharmaceuticals (NASDAQ SYRS) traded down 4.30% on Tuesday, reaching $15.37. 145,587 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $20.64 and its 200 day moving average price is $16.59. The company’s market cap is $403.62 million. Syros Pharmaceuticals has a 12 month low of $10.22 and a 12 month high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, equities analysts expect that Syros Pharmaceuticals will post ($2.09) EPS for the current fiscal year.
In other news, insider Eric R. Olson sold 2,500 shares of the business’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $23.59, for a total transaction of $58,975.00. Following the sale, the insider now owns 2,500 shares in the company, valued at approximately $58,975. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard A. Young sold 3,282 shares of the business’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total transaction of $72,499.38. Following the sale, the director now owns 423,383 shares in the company, valued at approximately $9,352,530.47. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,564 shares of company stock worth $476,803.
ILLEGAL ACTIVITY WARNING: “Syros Pharmaceuticals (SYRS) Receiving Somewhat Favorable Media Coverage, Analysis Finds” was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.thestockobserver.com/2017/09/12/syros-pharmaceuticals-syrs-receiving-somewhat-favorable-media-coverage-analysis-finds.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.